Source: https://www.clinicaltrialsarena.com/news/rege...ion-trial/

Quote:

---

The Phase III Covid-19 prevention trial, which will enroll approximately 2,000 patients at around 100 sites in the US , will investigate SARS-CoV-2 infection status.

---

Quote:

---

Meanwhile, the two Phase II/III treatment trials in hospitalized and non-hospitalized patients will involve approximately 1,850 and 1,050 patients, respectively, at around 150 sites across the US, Brazil, Mexico and Chile.

---

Source: https://www.nytimes.com/2020/07/09/health/reg...odies.html

Quote:

---

The Trump administration this week gave a major boost to Regeneron’s treatment, awarding the company $450 million to manufacture and supply as many as 300,000 doses as treatments or 1.3 million doses to prevent infection. That’s in addition to $160 million in federal money the company had already received to run clinical trials and ramp up manufacturing. After the treatment passed an initial safety study, Regeneron’s broader trials to evaluate the product’s efficacy got underway.

---

So, in aggregate, that's 4,900 patients.

Using same carefully selected phrase I used in my original post:

"I bet" they enrolled more subjects in their trials in one or two days -- than the total sum of our M/M and S/C.

"I bet" the administration awarded them $450M only after understanding there was efficacy after peeking at the data.

"I bet" our MOA was not lost in someone's Inbox in Mexico.

"I bet" Trump is talking about Regeneron and not CytoDyn.

These are all suppositions on my part.